DrSam Vigours

Dr Samuel Vigours is a medical advisor with the Centre for Health Economics Research and Evaluation (CHERE) at the University of Technology Sydney.

With over 6 years of clinical experience primarily as an Emergency Department Senior Resident Medical Officer and Intensive Care Registrar, followed by 6 years as an academic advisor and senior researcher, Dr Vigours has provided in-depth analyses and advice on evaluations for the Pharmaceutical Benefits Advisory Committee (PBAC), Clinical Evaluation Reports for the Therapeutic Goods Administration (TGA) and PICO Confirmations for the Medical Services Advisory Committee (MSAC).

Dr Vigours has also reviewed numerous clinical trial designs for the Cancer Australia Cancer Research Economics Support Team (CREST), co-authored the Review of the Discount Rate in the PBAC Guidelines and authored the topics on pharmaceutical price negotiations and funding decision-making in the recently published Health Technology Assessment (HTA) Review. Dr Vigours is currently working on a project partnered with NSW Health investigating clinical care processes that mitigate environmental damage, which will produce environmentally considered proposals in clinical processes for NSW hospitals, and is the chief investigator in a project aiming to quantify the costs and benefits afforded by population-based cancer screening.

Dr Vigours has extensive knowledge of the Australian healthcare system and the operation of the TGA, PBAC and MSAC. He also has a comprehensive understanding of the evaluation of clinical trial design, and how research outputs may be communicated to stakeholders and applied to the Australian population, with a unique perspective on how doctors, nursing staff, administration and policymakers may be aligned to produce optimum patient care and translate medical research into real-world outcomes.